SCHEMBL7199599

SCHEMBL7199599

COc1ccc2ccc3c(c2c1)C=C(C(=O)O)CO3

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PTGS1 P23219 1/20 0.47
PTGS2 P35354 1/20 0.47
ALOX5 P09917 3/20 0.45
MTNR1A P48039 4/20 0.44
MAOB P27338 1/20 0.44
SHMT2 P34897 1/20 0.44
NR1H4 Q96RI1 2/20 0.43
KDM4E B2RXH2 2/20 0.42
MEN1 O00255 1/20 0.41
HSP90AA1 P07900 1/20 0.41
GAA P10253 1/20 0.41
MAPT P10636 1/20 0.41
HTT P42858 1/20 0.41
KMT2A Q03164 1/20 0.41
ALDH1A1 P00352 2/20 0.39
POLB P06746 1/20 0.39
HPGD P15428 1/20 0.39
HSD17B10 Q99714 1/20 0.39
NPC1 O15118 1/20 0.39
NFKB1 P19838 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7204770 0.86 MTNR1A (0.50) PTGS1PTGS2ALOX5MTNR1AMAOB
SCHEMBL2014811 0.81 LMNA (0.47) ALOX5MAOBSHMT2NR1H4KDM4E
SCHEMBL3198679 0.80 MAOB (0.64) PTGS1PTGS2ALOX5MTNR1AMAOB
SCHEMBL19313390 0.79 HNF4A (0.50) PTGS1PTGS2ALOX5MTNR1AMAOB
SCHEMBL432850 0.77 ALOX5 (0.71) PTGS1PTGS2ALOX5MTNR1AMAOB
SCHEMBL5226489 0.75 PTGS1 (0.41) PTGS1PTGS2ALOX5MTNR1ASHMT2
SCHEMBL5763911 0.71 NR1H4 (0.62) ALOX5MAOBSHMT2NR1H4KDM4E
SCHEMBL6075764 0.69 NR1H4 (0.41) PTGS1PTGS2MTNR1AMAOBSHMT2
SCHEMBL9058391 0.69 MAOB (0.64) PTGS1PTGS2ALOX5MTNR1AMAOB
SCHEMBL5794944 0.68 MAPT (0.64) PTGS1PTGS2ALOX5MTNR1AMAOB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6602903-B2 Substituted O- and/or S heterocyclic compounds; powerful ligands for melatoninergic receptors. LES LABORATORIES SERVIER (FR) 2003-08-05 US disclosed
US-20020052400-A1 Substituted heterocyclic compounds ADIR ET COMPAGNIE 2002-05-02 US disclosed
US-6313160-B1 FOR THERAPY AND PROPHYLAXIS OF MELATONINERGIC DISORDERS ADIR ET COMPAGNIE (FR) 2001-11-06 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020052400-A1 Substituted heterocyclic compounds MTNR1A, MTNR1B, CBR1 PTGS1 570/4885PTGS2 792/4885ALOX5 567/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.